| Literature DB >> 30010810 |
Neneh Sallah1, Anne L Palser2, Simon J Watson2, Nazzarena Labo3, Gershim Asiki4, Vickie Marshall3, Robert Newton4, Denise Whitby3, Paul Kellam2,5, Inês Barroso1.
Abstract
Background: Kaposi sarcoma-associated herpesvirus (KSHV) establishes lifelong infection in the human host and has been associated with a variety of malignancies. KSHV displays striking geographic variation in prevalence, which is highest in sub-Saharan Africa. The current KSHV genome sequences available are all tumor cell line-derived or primary tumor-associated viruses, which have provided valuable insights into KSHV genetic diversity.Entities:
Mesh:
Substances:
Year: 2018 PMID: 30010810 PMCID: PMC6195662 DOI: 10.1093/infdis/jiy427
Source DB: PubMed Journal: J Infect Dis ISSN: 0022-1899 Impact factor: 5.226
Characteristics of Samples Used in This Study
| Name | Origin | K15 Type | K1 Type | New Typea | Sample Source | HIV Statusb | Clinical Presentation | Accession Number | Ref. |
|---|---|---|---|---|---|---|---|---|---|
| UG110 | Uganda | P | A5 | P1 | Saliva | 0 | Asymptomatic | ERS1615765 | … |
| UG114 | Uganda | P | A5 | P2 | Saliva | 0 | Asymptomatic | ERS1615766 | … |
| UG117 | Uganda | P | C1 | P2 | Saliva | 0 | Asymptomatic | ERS1615774 | … |
| UG118 | Uganda | M | B1 | M1 | Saliva | 0 | Asymptomatic | ERS1615777 | … |
| UG119 | Uganda | M | A5 | M1 | Saliva | 0 | Asymptomatic | ERS1615780 | … |
| UG12 | Uganda | P | B1 | P1 | Saliva | 1 | HIV + asymptomatic | ERS1615738 | … |
| UG120 | Uganda | P | B1 | P2 | Saliva | 0 | Asymptomatic | ERS1615783 | … |
| UG125 | Uganda | P | B1 | P1 | Saliva | 0 | Asymptomatic | ERS1615800 | … |
| UG126 | Uganda | P | B1 | P1 | Saliva | 0 | Asymptomatic | ERS1615707 | … |
| UG128 | Uganda | P | A5 | P1 | Saliva | 0 | Asymptomatic | ERS1615712 | … |
| UG129c | Uganda | P | B1 | P1 | Saliva | 0 | Asymptomatic | ERS1615715 | … |
| UG13 | Uganda | P | B1 | P1 | Saliva | 0 | Asymptomatic | ERS1615741 | … |
| UG131c | Uganda | M | B1 | M2 | Saliva | 0 | Asymptomatic | ERS1615723 | … |
| UG132 | Uganda | P | A5 | P2 | Saliva | 0 | Asymptomatic | ERS1615725 | … |
| UG133 | Uganda | P | B1 | P1 | Saliva | 0 | Asymptomatic | ERS1615727 | … |
| UG134 | Uganda | P | A5 | P1 | Saliva | 0 | Asymptomatic | ERS1615730 | … |
| UG136 | Uganda | P | B3 | P2 | Saliva | 0 | Asymptomatic | ERS1615737 | … |
| UG137 | Uganda | P | A5 | P1 | Saliva | 0 | Asymptomatic | ERS1615744 | … |
| UG141 | Uganda | P | B1 | P1 | Saliva | 0 | Asymptomatic | ERS1615761 | … |
| UG145 | Uganda | M | A5 | M1 | Saliva | 0 | Asymptomatic | ERS1615775 | … |
| UG146 | Uganda | P | A5 | P1 | Saliva | 0 | Asymptomatic | ERS1615778 | … |
| UG148 | Uganda | P | A5 | P1 | Saliva | 0 | Asymptomatic | ERS1615784 | … |
| UG149 | Uganda | P | A5 | P2 | Saliva | 0 | Asymptomatic | ERS1615786 | … |
| UG15 | Uganda | M | A5 | M1 | Saliva | 0 | Asymptomatic | ERS1615748 | … |
| UG151 | Uganda | P | B1 | P1 | Saliva | 0 | Asymptomatic | ERS1615793 | … |
| UG152 | Uganda | P | A5 | P1 | Saliva | 0 | Asymptomatic | ERS1615795 | … |
| UG155 | Uganda | P | B1 | P2 | Saliva | 0 | Asymptomatic | ERS1615706 | … |
| UG156 | Uganda | P | C1 | P1 | Saliva | 1 | HIV + asymptomatic | ERS1615711 | … |
| UG157 | Uganda | M | C1 | M1 | Saliva | 1 | HIV + asymptomatic | ERS1615714 | … |
| UG158 | Uganda | P | A5 | P1 | Saliva | 0 | Asymptomatic | ERS1615719 | … |
| UG159 | Uganda | P | A5 | P1 | Saliva | 0 | Asymptomatic | ERS1615721 | … |
| UG16 | Uganda | M | A5 | M1 | Saliva | 1 | HIV + asymptomatic | ERS1615752 | … |
| UG160 | Uganda | M | B1 | M2 | Saliva | 0 | Asymptomatic | ERS1615722 | … |
| UG162 | Uganda | P | B1 | P1 | Saliva | 0 | Asymptomatic | ERS1615729 | … |
| UG163 | Uganda | P | B1 | P1 | Saliva | 0 | Asymptomatic | ERS1615732 | … |
| UG164 | Uganda | P | A5 | P2 | Saliva | 0 | Asymptomatic | ERS1615736 | … |
| UG165 | Uganda | P | A5 | P1 | Saliva | 0 | Asymptomatic | ERS1615740 | … |
| UG166 | Uganda | P | A5 | P1 | Saliva | 0 | Asymptomatic | ERS1615743 | … |
| UG168 | Uganda | P | B1 | P1 | Saliva | 1 | HIV + asymptomatic | ERS1615750 | … |
| UG212 | Uganda | P | A5 | P1 | Saliva | 0 | Asymptomatic | ERS1615837 | … |
| UG219 | Uganda | M | B4 | M1 | Saliva | 0 | Asymptomatic | ERS1615860 | … |
| UG222 | Uganda | P | A5 | P1 | Saliva | 0 | Asymptomatic | ERS1615807 | … |
| UG226 | Uganda | P | A5 | P1 | Saliva | 1 | HIV + asymptomatic | ERS1615813 | … |
| UG237 | Uganda | M | B4 | M2 | Saliva | 0 | Asymptomatic | ERS1615851 | … |
| UG244 | Uganda | P | A5 | P1 | Saliva | 0 | Asymptomatic | ERS1615861 | … |
| BC1 | United States | M | A2 | M1 | B-cell line | 0 | PEL | U75698.1 | [ |
| BCBL1 | United States | P | A3 | P1 | B-cell line | 0 | PEL | HQ404500.1 | [ |
| DG1 | United States | P | A5 | P1 | Blood | 0 | KICS | JQ619843.1 | [ |
| GK18 | Greece | P | C3 | P1 | KS biopsy | 1 | Classic KS | AF148805.2 | [ |
| JSC1 | United States | P | C3 | P1 | B-cell line | 0 | EBV + PEL | GQ994935.1 | [ |
| ZM004 | Zambia | P | B1 | ? | KS biopsy | 1 | Classic KS | KT271453 | [ |
| ZM027 | Zambia | P | B1 | P2 | KS biopsy | 1 | Classic KS | KT271454 | [ |
| ZM091 | Zambia | P | A5 | P2 | KS biopsy | 1 | Classic KS | KT271455 | [ |
| ZM095 | Zambia | N | B4 | N | KS biopsy | 1 | Classic KS | KT271456 | [ |
| ZM102 | Zambia | P | B4 | P2 | KS biopsy | 1 | Classic KS | KT271457 | [ |
| ZM106 | Zambia | P | B1 | P1 | KS biopsy | 1 | Classic KS | KT271458 | [ |
| ZM108 | Zambia | P | B4 | P2 | KS biopsy | 1 | Classic KS | KT271459 | [ |
| ZM114 | Zambia | P | B3 | P2 | KS biopsy | 1 | Classic KS | KT271460 | [ |
| ZM116 | Zambia | P | B4 | P1 | KS biopsy | 1 | Classic KS | KT271461 | [ |
| ZM117 | Zambia | P | B4 | P2 | KS biopsy | 1 | Classic KS | KT271462 | [ |
| ZM118 | Zambia | P | B1 | P1 | KS biopsy | 1 | Classic KS | KT271463 | [ |
| ZM121 | Zambia | P | B1 | P2 | KS biopsy | 1 | Classic KS | KT271464 | [ |
| ZM123 | Zambia | P | B1 | P1 | KS biopsy | 1 | Classic KS | KT271465 | [ |
| ZM124 | Zambia | P | B1 | P1 | KS biopsy | 1 | Classic KS | KT271466 | [ |
| ZM128 | Zambia | N | B1 | N | KS biopsy | 1 | Classic KS | KT271467 | [ |
| ZM130 | Zambia | P | B3 | P2 | KS biopsy | 1 | Classic KS | KT271468 | [ |
| Japan1 | Japan | M | C3 | M1 | Cell line | 0 | Non-AIDS KS | LC200589 | [ |
| Miyako1 | Japan | M | C3 | M1 | KS biopsy | 0 | Non-AIDS KS | LC200586 | [ |
| Miyako2 | Japan | M | C3 | M1 | KS biopsy | 0 | Non-AIDS KS | LC200587 | [ |
| Miyako3 | Japan | M | C3 | M1 | KS biopsy | 0 | Non-AIDS KS | LC200588 | [ |
Abbreviations: EBV, Epstein-Barr virus; KICS, Kaposi sarcoma-associated herpesvirus inflammatory cytokine syndrome; KS, Kaposi sarcoma; PEL, primary effusion lymphoma.
aBased on whole-genome data.
bHIV status: 0, negative; 1, positive.
cBelong to the same household.
Figure 1.Whole-genome variation across 70 genomes. Line graph plotted across the genome showing the proportion of variant bases in a 1000-nucleotide (nt) sliding window where at least 1 Kaposi sarcoma-associated herpesvirus genome sequence has a single nucleotide polymorphism relative to the GK18 reference sequence. Grey bars indicate masked-out repeat regions.
Figure 2.Principal component analysis (PCA) separates strains by type and geographic origin. PCA of all Kaposi sarcoma-associated herpesvirus (KSHV) strains (45 new strains and 25 published strains) based on single-nucleotide polymorphisms relative to the GK18 reference sequence in a full-genome multiple-sequence alignment. A, Principal component 1 (PC 1) separates all strains based on type P (blue dotted circle) and type M (green dotted circle). B, PCA of central genome minus variable K1 and K15 genes shows some geographic clustering of KSHV strains, with separation of the African strains (black and red) compared to Western (blue) and Japanese (green).
Figure 3.Neighbor-net phylogenetic network based on complete genomes of all 70 Kaposi sarcoma-associated herpesvirus samples. Parallel edges depict conflicting phylogenetic signals. The samples clustered into 5 distinct types (dotted circles) designated types P1, P2, M1, M2, and N, and 1 outlier ZM004, which did not cluster well with any type and thus may be a putative intertype recombinant or a novel type. The tips are labeled to represent sample geographic origin: black (Uganda), red, (Zambia), blue (Western), and green (Japan).
Kaposi Sarcoma-Associated Herpesvirus Genes With Evidence of Recombination
| Gene | GARDa | Phi test | RDP4 | Breakpoint (Bootstrap Support) | Alignment length, Codons |
|---|---|---|---|---|---|
| K1 | Yes | Yes | Yes | 362(0.71) | 867 |
| ORF4 | Yes | Yes | Yes | 475 (0.86) | 1650 |
| ORF6 | Yes | Yes | No | 1622 (0.18) | 3399 |
| ORF9 | Yes | Yes | Yes | 408 (0.99) | 3036 |
| ORF11 | Yes | Yes | Yes | 462 (0.51) | 1221 |
| ORF21 | Yes | Yes | Yes | 931 (0.68) | 1740 |
| ORF48 | Yes | Yes | No | 909 (0.95) | 1206 |
| ORF64 | Yes | Yes | Yes | 6561 (0.35) | 7905 |
Abbreviations: AICc, Akaike information criterion; GARD, genetic algorithm recombination detection; KH, Kishino Hasegawa; ORF, open reading frame.
aGARD: both AICc and KH significant, Phi-test: P < .05, RDP4: breakpoints with P < .05 and supported by at least 2 methods (RDP, GENECONV, MAXCHI, CHIMAERA, BOOTSCAN, SISCAN, 3SEQ).
Figure 4.Evidence for recombination between different Kaposi sarcoma-associated herpesvirus types. A, Intertypic recombinant type M2. Bootscan plot comparing type M2 query with consensus sequence of types P2 (red), P1(green), M1(yellow), N (purple), and ZM004 (orange). B, Intratypic recombinant ZM091. Bootscan plot comparing ZM091 with consensus sequences of types P2 (red), P1(green), and ZM004 (orange). Shifting phylogenetic signals and fragmented genomes are indicative of the presence of recombination.